The GLP-1 receptor agonist liraglutide can slow down the progression of Alzheimer’s disease

Phase 1

• Conditions: Alzheimer's disease; MedDRA version: 14.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 10029205 - Nervous system disorders; Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

• Registration Number: EUCTR2011-000794-31-DK
• Lead Sponsor: Dept. of Pharmacology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-06-01
• Last Update Posted: 19 September 2016

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Patients diagnosed with AD by MMSE score and/or spinal puncture (If MMSE score is between 18-21 the patient is diagnosed by clinical symptoms only. If the MMSE score is > 22 a spinal puncture will be performed to diagnose the patient)
Age = 50 years and = 80 years

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 20
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 20

Exclusion Criteria

Diabetes mellitus
Liver or kidney insufficiency (alanine transferase levels more tha twice upper normal, plasma creatinine > 130µmol/l), clinical relevant anaemia
Current or earlier presence of another CNS disease (except for well-treated depression) or clinical relevant liver disease, kidney disease or endocrinological disease (except hypothyreoism).
Current or history of chronic or acute pancreatitis
If patients are treated with SSRI or SSRI similar drugs or antihypertensives this treatment should be stable
Claustrophobia or other missing co-orporation
Severe overweight > 130kg
Ferro-magnetic prosthesis, pacemaker or other metals incorporated in the body
Significant abnormities in the brain detected by MR scanning

Known abuse of alcohol or drugs
Every disease or treatment that the head investigator considers to have a possible effect on results of the study
Allergy to the drugs or diagnosing procedure used in the study
Participation in a clinical study 3 months prior to inclusion in this study
Patients who have previously participated in investigations with isotopes or ionizing radiation

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified